Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generics Coverage Worsens Under Medicare Plans In 2021

AAM Urges Policymakers To Initiate Medicare Part D Reform

Executive Summary

Based on the latest AAM-sponsored study by Avalere Health, the US off-patent industry association has asked policymakers to initiate Medicare Part D reforms. Generic prescription drugs are only placed on generic tiers 45% of the time in 2021, a significant decrease from the 64% seen in 2016.

You may also be interested in...



Medicare Plans Are Discouraging Generics Use

An AAM-sponsored study by researcher Avalere Health has concluded that Medicare Part D policy changes have led to generics being placed on non-generic tiers 53% of the time in 2020, with generics placed on the ‘preferred generic’ Tier 1 just 10% of the time.

Laurus Labs Expands Capacity To Meet API Demand

Laurus Labs has reported a 70% jump in annual revenues after what the company described as an “extraordinary year.” The firm has decided to expand its current capacities to meet the increased demand for third-party API sales and is looking to file eight to ten ANDAs next year as it sees “many long-term opportunities in the US generics space.”

Beximco’s Global Expansion Leads To Export Rise

Bangladesh’s Beximco has reported growth in export sales on the back of the company’s expansion into new international markets. The company delivered strong financial results overall for the third quarter of fiscal 2021, including double-digit growth on the domestic front. 

Topics

UsernamePublicRestriction

Register

GB150763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel